SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  FORM 8-K

                                CURRENT REPORT

                      Pursuant to Section 13 or 15(d) of 
                      the Securities Exchange Act of 1934


        Date of Report (Date of earliest event reported):  June 24, 1997



                            COPLEY PHARMACEUTICAL, INC.
             (Exact name of registrant as specified in its charter)

                                   Delaware
        (State or other jurisdiction of incorporation or organization) 





        0-20126                                         04-2514637
(Commission File Number)                     (IRS Employer Identification No.)





            25 John Road
        Canton, Massachusetts                               02021
(Address of principal executive offices)                  (Zip Code)







                                 (617) 821-6111
               (Registrant's telephone number, including area code)











Item 5.     Other Events


Copley Pharmaceutical, Inc. (Nasdaq: CPLY) announced a number of cost 
reduction initiatives.  Cumulatively, these decisions will result in a one 
time charge of approximately $1.6 million before taxes, or $0.05 per share 
after taxes, to be taken in the current quarter.  The Company is discontinuing 
its partnership participation in MIR Pharmaceutical, a company formed to 
manufacture and sell pharmaceutical products in Russia and has decided to 
discontinue funding a collaborative effort in the field of ophthalmology.   
Additionally, the Company announced a small reduction in its workforce.

"Given the current market conditions faced by the generic pharmaceutical 
industry, Copley has decided not to devote further  resources to these two
business ventures," said Kenneth N. Larsen, Copley's Chairman of the Board.  
"The limited workforce reduction responds to the changing needs of the 
Company's business and will help improve Copley's competitive position."

The Company also announced that United States District Judge Joseph Tauro 
accepted its plea of guilty to a one-count Information alleging a violation of 
the United States Code.  The Company's guilty plea was part of an agreement 
reached with the Massachusetts U.S. Attorney, which had been disclosed on May
28, 1997.  As the plea agreement anticipated, Judge Tauro fined the Company 
$10.65 million. As previously disclosed, the Company is revising its reserve 
for product recall and litigation expenses and will record an after tax charge
to earnings of $2 million, or $0.10 per share in the current quarter.

Kenneth N. Larsen, Copley's Chairman of the Board, commented, "Copley is 
pleased to have this investigation behind it.  As the United States Attorney 
acknowledged, his three-year probe found no evidence that any person suffered 
any injury as a result of the Company's conduct.  The closure achieved today, 
together with previously announced cost savings and restructuring initiatives, 
will permit Copley to continue to compete as a significant force in the 
generic pharmaceutical business."

Copley, a Canton, Massachusetts-based company founded in 1972, currently 
employs approximately 400 people in Research and Development, Quality 
Assurance, Quality Control, Engineering, Production, Regulatory Affairs, Sales
and Marketing and International Registration.  Copley is a leading 
manufacturer and marketer of a broad range of multi-source prescription and 
over-the-counter pharmaceuticals.  The firm markets its products to 
distributors, retail chains, wholesalers, hospitals, government agencies, and 
managed care companies. 

Forward-looking statements (statements that are not historical fact) are made 
pursuant to the safe harbor provisions of the Private Securities Litigation 
Reform Act of 1995.  Investors are cautioned that all forward-looking 
statements involve risks and uncertainties, including those risks and 
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission, copies of which are available from the Company.



SIGNATURE 

Pursuant to the requirements of the Securities Exchange Act of 1934, the 
Registrant has duly caused this report to be signed on its behalf by the 
undersigned hereunto duly authorized.

                                                                               
June 24, 1997                                 COPLEY PHARMACEUTICAL, INC.


                                            /s/ Ken E. Starkweather
                                           ---------------------------
                                                Ken E. Starkweather
                                        Vice President - Finance and Treasurer 
                                             Principal Financial Officer
[{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 4879}]
{"company-data": {"conformed-name": "COPLEY PHARMACEUTICAL INC", "cik": "0000829987", "assigned-sic": "2834", "irs-number": "042514637", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-20126", "film-number": "97629037"}, "business-address": {"street1": "25 JOHN RD ST 13TH FL", "city": "CANTON", "state": "MA", "zip": "02021", "phone": "6178216111"}}
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  FORM 8-K

                                CURRENT REPORT

                      Pursuant to Section 13 or 15(d) of 
                      the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported):  June 24, 1997

                            COPLEY PHARMACEUTICAL, INC.
             (Exact name of registrant as specified in its charter)

                                   Delaware
        (State or other jurisdiction of incorporation or organization) 

        0-20126                                         04-2514637
(Commission File Number)                     (IRS Employer Identification No.)

            25 John Road
        Canton, Massachusetts                               02021
(Address of principal executive offices)                  (Zip Code)

                                 (617) 821-6111
               (Registrant's telephone number, including area code)

Item 5.     Other Events

Copley Pharmaceutical, Inc. (Nasdaq: CPLY) announced a number of cost 
reduction initiatives.  Cumulatively, these decisions will result in a one 
time charge of approximately $1.6 million before taxes, or $0.05 per share 
after taxes, to be taken in the current quarter.  The Company is discontinuing 
its partnership participation in MIR Pharmaceutical, a company formed to 
manufacture and sell pharmaceutical products in Russia and has decided to 
discontinue funding a collaborative effort in the field of ophthalmology.   
Additionally, the Company announced a small reduction in its workforce.

"Given the current market conditions faced by the generic pharmaceutical 
industry, Copley has decided not to devote further  resources to these two
business ventures," said Kenneth N. Larsen, Copley's Chairman of the Board.  
"The limited workforce reduction responds to the changing needs of the 
Company's business and will help improve Copley's competitive position."

The Company also announced that United States District Judge Joseph Tauro 
accepted its plea of guilty to a one-count Information alleging a violation of 
the United States Code.  The Company's guilty plea was part of an agreement 
reached with the Massachusetts U.S. Attorney, which had been disclosed on May
28, 1997.  As the plea agreement anticipated, Judge Tauro fined the Company 
$10.65 million. As previously disclosed, the Company is revising its reserve 
for product recall and litigation expenses and will record an after tax charge
to earnings of $2 million, or $0.10 per share in the current quarter.

Kenneth N. Larsen, Copley's Chairman of the Board, commented, "Copley is 
pleased to have this investigation behind it.  As the United States Attorney 
acknowledged, his three-year probe found no evidence that any person suffered 
any injury as a result of the Company's conduct.  The closure achieved today, 
together with previously announced cost savings and restructuring initiatives, 
will permit Copley to continue to compete as a significant force in the 
generic pharmaceutical business."

Copley, a Canton, Massachusetts-based company founded in 1972, currently 
employs approximately 400 people in Research and Development, Quality 
Assurance, Quality Control, Engineering, Production, Regulatory Affairs, Sales
and Marketing and International Registration.  Copley is a leading 
manufacturer and marketer of a broad range of multi-source prescription and 
over-the-counter pharmaceuticals.  The firm markets its products to 
distributors, retail chains, wholesalers, hospitals, government agencies, and 
managed care companies. 

Forward-looking statements (statements that are not historical fact) are made 
pursuant to the safe harbor provisions of the Private Securities Litigation 
Reform Act of 1995.  Investors are cautioned that all forward-looking 
statements involve risks and uncertainties, including those risks and 
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission, copies of which are available from the Company.

SIGNATURE 

Pursuant to the requirements of the Securities Exchange Act of 1934, the 
Registrant has duly caused this report to be signed on its behalf by the 
undersigned hereunto duly authorized.

                                                                               
June 24, 1997                                 COPLEY PHARMACEUTICAL, INC.

                                            /s/ Ken E. Starkweather
                                           ---------------------------
                                                Ken E. Starkweather
                                        Vice President - Finance and Treasurer 
                                             Principal Financial Officer